OBJECTIVES: Current guidelines provide limited evidence as to which patients with urinary tract infection (UTI) require hospitalisation. We evaluated the currently used triage routine and tested whether a set of criteria including biomarkers like proadrenomedullin (proADM) and urea have the potential to improve triage decisions. METHODS: Consecutive adults with UTI presenting to our emergency department (ED) were recruited and followed for 30 days. We defined three virtual triage algorithms, which included either guideline-based clinical criteria, optimised admission proADM or urea levels in addition to a set of clinical criteria. We compared actual treatment sites and observed adverse events based on the physician judgment with the proportion of patients assigned to treatment sites according to the three virtual algorithms. Adverse outcome was defined as transfer to the intensive care unit (ICU), death, recurrence of UTI or rehospitalisation for any reason. RESULTS: We recruited 127 patients (age 61.8 ± 20.8 years; 73.2 % females) and analysed the data of 123 patients with a final diagnosis of UTI. Of these 123 patients, 27 (22.0 %) were treated as outpatients. Virtual triage based only on clinical signs would have treated only 22 (17.9 %) patients as outpatients, with higher proportions of outpatients equally in both biomarker groups (29.3 %; p = 0.02). There were no significant differences in adverse events between outpatients according to the clinical (4.5 %), proADM (2.8 %) or urea groups (2.8 %). The mean length of stay was 6.6 days, including 2.2 days after reaching medical stability. CONCLUSIONS: Adding biomarkers to clinical criteria has the potential to improve risk-based triage without impairing safety. Current rates of admission and length of stay could be shortened in patients with UTI.
OBJECTIVES: Current guidelines provide limited evidence as to which patients with urinary tract infection (UTI) require hospitalisation. We evaluated the currently used triage routine and tested whether a set of criteria including biomarkers like proadrenomedullin (proADM) and urea have the potential to improve triage decisions. METHODS: Consecutive adults with UTI presenting to our emergency department (ED) were recruited and followed for 30 days. We defined three virtual triage algorithms, which included either guideline-based clinical criteria, optimised admission proADM or urea levels in addition to a set of clinical criteria. We compared actual treatment sites and observed adverse events based on the physician judgment with the proportion of patients assigned to treatment sites according to the three virtual algorithms. Adverse outcome was defined as transfer to the intensive care unit (ICU), death, recurrence of UTI or rehospitalisation for any reason. RESULTS: We recruited 127 patients (age 61.8 ± 20.8 years; 73.2 % females) and analysed the data of 123 patients with a final diagnosis of UTI. Of these 123 patients, 27 (22.0 %) were treated as outpatients. Virtual triage based only on clinical signs would have treated only 22 (17.9 %) patients as outpatients, with higher proportions of outpatients equally in both biomarker groups (29.3 %; p = 0.02). There were no significant differences in adverse events between outpatients according to the clinical (4.5 %), proADM (2.8 %) or urea groups (2.8 %). The mean length of stay was 6.6 days, including 2.2 days after reaching medical stability. CONCLUSIONS: Adding biomarkers to clinical criteria has the potential to improve risk-based triage without impairing safety. Current rates of admission and length of stay could be shortened in patients with UTI.
Authors: James D Chalmers; Mudher Al-Khairalla; Philip M Short; Tom C Fardon; John H Winter Journal: J Antimicrob Chemother Date: 2010-02-23 Impact factor: 5.790
Authors: W C Albrich; K Rüegger; F Dusemund; R Bossart; K Regez; U Schild; A Conca; P Schuetz; T Sigrist; A Huber; B Reutlinger; B Müller Journal: Swiss Med Wkly Date: 2011-07-30 Impact factor: 2.193
Authors: Delia Scholes; Thomas M Hooton; Pacita L Roberts; Kalpana Gupta; Ann E Stapleton; Walter E Stamm Journal: Ann Intern Med Date: 2005-01-04 Impact factor: 25.391
Authors: Kyuseok Kim; Christopher C Lee; Joong Eui Rhee; Gil Joon Suh; Hwi-Jae Lee; Hong Bin Kim; Adam J Singer Journal: Acad Emerg Med Date: 2008-04 Impact factor: 3.451
Authors: Philipp Schuetz; Marcel Wolbers; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Thomas Fricker; Claudine Blum; Ursula Schild; Nils G Morgenthaler; Ronald Schoenenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Mueller Journal: Crit Care Date: 2010-06-08 Impact factor: 9.097
Authors: Mirjam Christ-Crain; Nils G Morgenthaler; Joachim Struck; Stephan Harbarth; Andreas Bergmann; Beat Müller Journal: Crit Care Date: 2005-11-15 Impact factor: 9.097
Authors: Daniel Drozdov; Anja Thomer; Marc Meili; Stefanie Schwarz; Rita Bossart Kouegbe; Katharina Regez; Merih Guglielmetti; Ursula Schild; Antoinette Conca; Petra Schäfer; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Alexander Litke; Philipp Schuetz; Andreas Huber; Ulrich Bürgi; Christoph A Fux; Andreas Bock; Beat Müller; Werner C Albrich Journal: Trials Date: 2013-03-22 Impact factor: 2.279
Authors: Daniel Widmer; Daniel Drozdov; Kristina Rüegger; Alexander Litke; Birsen Arici; Katharina Regez; Merih Guglielmetti; Ursula Schild; Antoinette Conca; Petra Schäfer; Rita Bossart Kouegbe; Barbara Reutlinger; Claudine Blum; Philipp Schuetz; Sarosh Irani; Andreas Huber; Ulrich Bürgi; Beat Müller; Werner C Albrich Journal: J Clin Med Date: 2014-03-14 Impact factor: 4.241
Authors: Christian Hans Nickel; Anna Sarah Messmer; Leyla Ghanim; Julia Ilsemann-Karakoumis; Sven Giersdorf; Sabine Hertel; Susanne Ernst; Nicolas Geigy; Roland Bingisser Journal: Medicine (Baltimore) Date: 2016-01 Impact factor: 1.817